AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28241355
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel for 12 months
Trial: 28241355
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel for 12 months
Trial: 26897544
Drug: Vocal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocal group therapy intervention
Trial: 23040521
Drug: High-dose arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose arginine (500 mg · kg(‐1) · d(‐1))
Trial: 23040521
Drug: Low-dose arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose arginine (100 mg · kg(‐1) · d(‐1)) combined with sodium phenylbutyrate (500 mg · kg(‐1) · d(‐1))
Trial: 17426000
Drug: Cephalothin V
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin V (2.0 g) intravenous 30 min before the operation
Trial: 17426000
Drug: Ozone injection
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone injection (6-10 ml ozone at 40 microg/ml) into the discs and 10 ml ozone into the paravertebral space
Trial: 15668261
Drug: No axillary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No axillary treatment
Trial: 7879930
Drug: Dexmedetomidine low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine low dose (targeting plasma concentration of 0.15 ng/ml)
Trial: 7879930
Drug: Dexmedetomidine medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine medium dose (targeting plasma concentration of 0.30 ng/ml)
Trial: 7879930
Drug: Dexmedetomidine high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine high dose (targeting plasma concentration of 0.45 ng/ml)
Trial: 26814038
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 3 mcg · kg(‐1) plus oral placebo (Group IN DEX)
Trial: 26814038
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate 50 mg · kg(‐1) plus intranasal saline placebo (Group CH)
Trial: 26922170
Drug: Pemetrexed and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed and bevacizumab maintenance therapy
Trial: 21289261
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of progesterone
Trial: 16707870
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (erosion only)
Trial: 15013894
Drug: Daily patching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily patching (> or =2 hours a day) combined with at least 1 hour of near activities
Trial: 11709795
Drug: Oral washes
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral washes using a PCR detection system based on Pneumocystis major surface glycoprotein primers
Trial: 11709795
Drug: Oral washes
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral washes using a PCR detection system based on mitochondrial large subunit rRNA primers
Trial: 9041342
Drug: 40‐microg S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40‐microg S subunit vaccine
Trial: 9041342
Drug: 10‐microg S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐microg S subunit vaccine
Trial: 9041342
Drug: mixed particle
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mixed particle vaccine (pre‐S1, pre‐S2, and S subunit particles)
Trial: 2152972
Drug: ACTH(4-9) analogue,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH(4-9) analogue, Org 2766 (high dose: 1 mg/m²)
Trial: 2152972
Drug: ACTH(4-9) analogue,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH(4-9) analogue, Org 2766 (low dose: 0.25 mg/m²)
Trial: 7510078
Drug: FK‐506 intelligent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK‐506 intelligent dosing system (IDS)
Trial: 2133624
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g Mg pidolate (MAG2) three times a day for one month
Trial: 30311367
Drug: Dapagliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (5 mg per day)
Trial: 28588304
Drug: Energy-restriction treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-restriction treatments (VLCK and LC diets)
Trial: 24381190
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg of salbutamol
Trial: 23172751
Drug: Lupuzor (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupuzor (200 μg) subcutaneously every 4 weeks
Trial: 23172751
Drug: Lupuzor (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupuzor (200 μg) subcutaneously every 2 weeks
Trial: 19309420
Drug: Home-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based intervention training parents to work with children through modelling and coaching by teachers during weekly home visits
Trial: 16397402
Drug: 5‐HT2A -1438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT2A -1438 A/G polymorphism
Trial: 8237402
Drug: Lomefloxacin tablet
DrugBank: Lomefloxacin (DB00978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomefloxacin tablet (400 mg)
Trial: 8237402
Drug: Lomefloxacin capsule
RxNorm normalized name: lomefloxacin Oral Capsule
DrugBank: Lomefloxacin (DB00978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomefloxacin capsule (400 mg)
Trial: 3524844
Drug: Rociverine 20
RxNorm normalized name: rociverine
DrugBank: Rociverine (DB13581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rociverine 20 mg
Trial: 3524844
Drug: Flavoxate 200
RxNorm normalized name: flavoxate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavoxate 200 mg
Trial: 10227010
Drug: Estrogen-progestin therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-progestin therapy
Trial: 23796998
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg for 19 doses over 5 years)
Trial: 23796998
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard adjuvant systemic therapy alone)
Trial: 20842110
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 or 40 mg daily for 4 weeks
Trial: 20842110
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continued current therapy)
Trial: 18613278
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo or active diabetes medications)
Trial: 18613278
Drug: Rosiglitazone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone monotherapy versus placebo
Trial: 18613278
Drug: Rosiglitazone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone monotherapy versus sulfonylurea/metformin monotherapy
Trial: 18613278
Drug: Sulfonylurea +
RxNorm normalized name: sulfanilylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea + rosiglitazone versus sulfonylurea monotherapy
Trial: 18613278
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + rosiglitazone versus metformin monotherapy
Trial: 18613278
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + rosiglitazone versus metformin + sulfonylurea
Trial: 18613278
Drug: Sulfonylurea +
RxNorm normalized name: sulfanilylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea + metformin + rosiglitazone versus sulfonylurea + metformin
Trial: 18613278
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + rosiglitazone versus insulin monotherapy
Trial: 12849762
Drug: L-dopa therapy
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa therapy (ON condition)
Trial: 12849762
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (OFF condition)
Trial: 29920978
Drug: Vortioxetine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (5 to 20 mg once daily)
Trial: 22324948
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) 150 mg daily
Trial: 17335316
Drug: Combination trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination trials (antidepressant and antipsychotic)
Trial: 15064262
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 micro g*kg(‐1) iv followed by 0.5 micro g*kg(‐1)*hr(‐1) infusion with morphine PCA (2 mg bolus, five minutes lockout, 2 mg*hr(‐1) infusion)
Trial: 15064262
Drug: Tramadol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1.5 mg*kg(‐1) pre‐mixed with midazolam 30 micro g*kg(‐1) iv followed by tramadol PCA (20 mg bolus, five minute lockout, 20 mg*hr(‐1) infusion)
Trial: 12126906
Drug: Oka/Merck varicella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oka/Merck varicella vaccine (Group A: 50,000 PFU, Group B: 16,000 PFU)
Trial: 7861197
Drug: Brodimoprim 200mg
RxNorm normalized name: brodimoprim
DrugBank: Brodimoprim (DB13795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodimoprim 200mg tablet once daily for 8 to 12 days (including a loading dose of 2 tablets on the first day)
Trial: 7861197
Drug: Doxycycline 100mg
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100mg tablet once daily for 8 to 12 days (including a loading dose of 2 tablets on the first day)
Trial: 28318515
Drug: Statin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin administration 24 hours or less preoperatively
Trial: 28318515
Drug: Statin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin administration 24 to 72 hours preoperatively
Trial: 28318515
Drug: Statin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin administration more than 72 hours or no dose
Trial: 28318515
Drug: Statin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin dose of 20 mg or less
Trial: 28318515
Drug: Statin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin dose of more than 20 mg
Trial: 7639374
Drug: Interpleural infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interpleural infusion of 2% lidocaine
Trial: 31228006
Drug: Propofol (2.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.0, 1.5, and 1.2 mg/kg for young, middle, and elderly groups respectively)
Trial: 31228006
Drug: Thiopental (5.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (5.0, 4.0, and 3.0 mg/kg for young, middle, and elderly groups respectively)
Trial: 25158925
Drug: Lubiprostone (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone (48 μg/day) for 4 weeks
Trial: 25158925
Drug: Lubiprostone (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone (24 μg twice daily) for 48 weeks
Trial: 21461761
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 mg/kg)
Trial: 2418707
Drug: 375 Units
RxNorm normalized name: CHOLECALCIFEROL 3375 UNITS/FOLIC 1MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 Units of Heparin/kg body weight injected into the right atrium (group 1)
Trial: 2418707
Drug: 375 Units
RxNorm normalized name: CHOLECALCIFEROL 3375 UNITS/FOLIC 1MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 Units of Heparin/kg body weight injected into the ascending aorta (group 2)
Trial: 29371133
Drug: Inhaled hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled hypertonic saline (HS), 7% NaCl, 4 mL, single dose
Trial: 27347698
Drug: Craniosacral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniosacral therapy (10 sessions)
Trial: 25152289
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of rocuronium 0.06 mg/kg (Group II)
Trial: 25152289
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of rocuronium 0.075 mg/kg (Group III)
Trial: 25152289
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of rocuronium 0.1 mg/kg (Group IV)
Trial: 25152289
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo injection (Group I)
Trial: 18154225
Drug: Preventive educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive educational programme including topical application of 1.23% acidulated fluoride phosphate, pH 3.5, every 6 months
Trial: 10361960
Drug: Moclobemide (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (450 mg)
Trial: 7742165
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration to healthy volunteers with behaviour pattern A (competitive and aggressive)
Trial: 7742165
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration to healthy volunteers with behaviour pattern B
Trial: 2373127
Drug: Cholestyramine 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 24 g/day for 4 days with piroxicam 20 mg p.o.
Trial: 2373127
Drug: Cholestyramine 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 24 g/day for 4 days with tenoxicam 20 mg p.o.
Trial: 6930320
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B - sequential regimens consisting of azacytidine, cyclophosphamide, prednisone, 6-mercaptopurine, methotrexate, plus BCG
Trial: 24554519
Drug: Micronutrients (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrients (various doses)
Trial: 24554519
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (nonrandomized, no treatment)
Trial: 24554519
Drug: Micronutrients (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrients (continued treatment)
Trial: 24554519
Drug: Micronutrients (stopped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrients (stopped treatment)
Trial: 17227493
Drug: Pharmacological androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological androgen deprivation (flutamide 250 mg orally three times/day and leuprolide acetate 7.5 mg injection) for 7 days
Trial: 15202756
Drug: 35 percent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 percent hydrogen peroxide gel application for 30 minutes (Group 1)
Trial: 15202756
Drug: 38 percent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 38 percent hydrogen peroxide gel application for 30 minutes (Group 2)
Trial: 15202756
Drug: 10 percent
RxNorm normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 percent carbamide peroxide at-home bleaching agent for 60 minutes (combined with Group 1 and Group 2)
Trial: 456997
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage haloperidol (50 to 100 mg daily)
Trial: 456997
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (10 mg haloperidol and 150 to 300 mg levomepromazin)
Trial: 31800306
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) up to 2700 mg/day for 12 weeks
Trial: 25460556
Drug: High-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual therapy (HDDT) - rabeprazole 20 mg and amoxicillin 750 mg, 4 times/day for 14 days (group A1)
Trial: 25460556
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy for 10 days (group B1)
Trial: 25460556
Drug: Clarithromycin-containing triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin-containing triple therapy for 7 days (group C1)
Trial: 25460556
Drug: High-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual therapy (HDDT) for 14 days (group A2)
Trial: 25460556
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy for 10 days (group B2)
Trial: 25460556
Drug: Levofloxacin-containing triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin-containing triple therapy for 7 days (group C2)
Trial: 16552832
Drug: SSP electro-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSP electro-therapy
Trial: 10506613
Drug: Vinblastine (V)
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinblastine (V) 4 mg/m(2) by intravenous bolus weekly for 6 weeks followed by 2 weeks off
Trial: 10506613
Drug: Vinblastine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine plus estramustine phosphate (EM-V) 600 mg/m(2) PO days 1 through 42, repeated every 8 weeks
Trial: 6822051
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of radioactive aerosol while sitting, lying, and breathing at an increased rate.
Trial: 31683341
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg BD)
Trial: 31683341
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Metformin (500 mg BD) and Pioglitazone (15 mg BD)
Trial: 31683341
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Metformin and Pioglitazone
Trial: 24865525
Drug: Intensive Repeated
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive Repeated Mailings (IRM) - 10 booklets and additional supplemental materials mailed monthly over 18 months
Trial: 20170774
Drug: Manipulative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulative therapy in addition to usual care
Trial: 15790691
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (25‐100 mg)
Trial: 10207355
Drug: Chemotherapy to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy to all household members at the commencement of the study (18-month interval)
Trial: 10207355
Drug: Chemotherapy to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy to all household members at commencement and regular health education throughout the study period
Trial: 10207355
Drug: Chemotherapy to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy to all household members at commencement and subsequent chemotherapy to all children at intervals of 6 months
Trial: 10207355
Drug: Chemotherapy to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy to all household members at commencement, subsequent chemotherapy to all children at intervals of 6 months, and regular health education throughout the study period
Trial: 7878975
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 3 × 10^8/kg unaltered donor bone marrow cells perioperatively
Trial: 31756496
Drug: Brigatinib 90
RxNorm normalized name: brigatinib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 90 mg once daily (arm A)
Trial: 31756496
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg once daily with a 7-day lead-in at 90 mg (arm B)
Trial: 28512009
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) 50mg administered 1 hour before extinction training
Trial: 25388434
Drug: Intraduodenal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose infusion at 2 kcal/min
Trial: 21522004
Drug: Comparator (efavirenz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (efavirenz in STARTMRK; optimized background therapy in BENCHMRK)
Trial: 11179521
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and phenprocoumon
Trial: 7979564
Drug: Pulsatile oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile oxytocin infusion (one minute of infusion every five minutes)